Media headlines about Glaukos Corporation (NYSE:GKOS) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Glaukos Corporation earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Zacks Investment Research Lowers Glaukos Corporation (GKOS) to Hold (americanbankingnews.com)
- Abbott Laboratories (ABT) registers a price change of 0.20% while Glaukos Corporation (GKOS) finishes with a flow of … – Stocks Gallery (stocksgallery.com)
- Glaukos Corporation (GKOS) Downgraded to Sell at BidaskClub (americanbankingnews.com)
- Glaukos Corporation (NYSE:GKOS) Expected to Post Quarterly Sales of $43.20 Million (americanbankingnews.com)
- Glaukos Corporation (GKOS) Raised to Buy at Zacks Investment Research (americanbankingnews.com)
Glaukos Corporation (NYSE:GKOS) traded up 2.99% during midday trading on Tuesday, reaching $38.54. 380,166 shares of the company traded hands. The firm has a 50-day moving average price of $41.07 and a 200-day moving average price of $43.25. The firm’s market capitalization is $1.33 billion. Glaukos Corporation has a one year low of $28.26 and a one year high of $52.49.
A number of equities research analysts have recently issued reports on GKOS shares. Zacks Investment Research cut shares of Glaukos Corporation from a “buy” rating to a “hold” rating in a research report on Monday. BidaskClub cut shares of Glaukos Corporation from a “hold” rating to a “sell” rating in a research report on Saturday. Piper Jaffray Companies reissued a “buy” rating and issued a $56.00 target price on shares of Glaukos Corporation in a research report on Thursday, August 3rd. Finally, Roth Capital reduced their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. Glaukos Corporation presently has a consensus rating of “Buy” and a consensus target price of $52.33.
ILLEGAL ACTIVITY NOTICE: “Glaukos Corporation (NYSE:GKOS) Given Coverage Optimism Rating of 0.23” was published by BBNS and is owned by of BBNS. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/glaukos-corporation-nysegkos-earns-coverage-optimism-score-of-0-23-updated-updated-updated/1194361.html.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with our FREE daily email newsletter.